Search clinical trials for: Hodgkin's Lymphoma

Total 10620 results

Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)

Lymphoma, Non-Hodgkin

United States
Joseph Tuscano
Spectrum Pharmaceuticals, Inc

Active, not recruiting

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Relapsed Non Hodgkin Lymphoma | Refractory Non Hodgkin Lymphoma

United States
Scripps Health

Completed

Nonmyeloablative Allogeneic Transplant (Mini-allo)

Melanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Ovarian Cancer | Thymoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia and other conditions

United States
Jennifer Amengual

Completed

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi)

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Lymphoid Malignancies | Non-hodgkin Lymphoma

United States
Scripps Health

Completed

Unrelated Donor Stem Cell Transplantation

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Small Lymphocytic Lymphoma | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Myeloproliferative... and other conditions

United States
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma | Plasma Cell Myeloma

United States
Eisai Co., Ltd.

Completed

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Japan
Masonic Cancer Center, University of Minnesota

Completed

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Follicular Lymphoma | Multiple Myeloma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Indolent B Cell Lymphoma | Primary Mediastinal Lymphoma

United States
Seoul National University Hospital
Gyeongsang National University Hospital; Hallym University Medical Center; Kyunghee...

Terminated

Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL) (MG4101)

CD20-positive Non-Hodgkin Lymphoma

Korea, Republic of
Adagene Inc

Completed

Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Solid Tumors, Non-Hodgkin Lymphoma

United States
Yazeed Sawalha

Withdrawn

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Worldwide Clinical Trials

Suspended

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

B-cell Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
Biogen; CTI BioPharma

Completed

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Lymphoma

United States
Nordic Nanovector
ICON Clinical Research

Active, not recruiting

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
National Cancer Institute (NCI)

Terminated

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Recurrent...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
Göteborg University
Vastra Gotaland Region

Completed

Acute Appendicitis: Active Observation With and Without Antibiotics

Appendicitis

Sweden
Molecular Templates, Inc.

Terminated

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma | Non-hodgkin Lymphoma,B Cell

United States
Molecular Templates, Inc.

Terminated

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

Non-hodgkin Lymphoma

United States
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Suspended

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | CD20 Positive | Aggressive Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Unclassifiable | Intravascular Large B-Cell Lymphoma | T-Cell/Histiocyte-Rich...

United States
Andres J. M. Ferreri
Amgen

Completed

Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia (ProRom)

Non-Hodgkin Lymphoma

Italy
Hoffmann-La Roche
Institute of Cancer Research, United Kingdom; German Low Grade Lymphoma Study...

Completed

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Non-Hodgkin's Lymphoma

Italy, Belgium, Canada, United Kingdom, Australia, China, Germany, United States, Russian Federation, Spain, Taiwan, Israel, Czechia, Hungary, Japan, France, Finland, Sweden
University of Aarhus

Active, not recruiting

Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Malignant Lymphoma

Netherlands, Norway, Denmark, Finland, Sweden
Denovo Biopharma LLC

Completed

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

Diffuse Large B-Cell Lymphoma

United States, China
Opna-IO LLC

Completed

A Study of PLX2853 in Advanced Malignancies.

Follicular Lymphoma | Small Cell Lung Cancer | Solid Tumor | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Ovarian Clear Cell Carcinoma | Uveal Melanoma | Advanced Malignancies

United States
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Fox Chase Cancer Center
Merck Sharp & Dohme LLC

Terminated

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Lymphoma, T-Cell, Peripheral

United States
RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; Shanghai Zhongshan... and other collaborators

Completed

Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (AMBLE)

Pulmonary Arterial Hypertension

China
Fondazione Italiana Linfomi ONLUS

Completed

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Follicular Non-Hodgkin's Lymphoma

Italy
Memorial Sloan Kettering Cancer Center
Columbia University; Genentech, Inc.

Completed

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

Non-Hodgkin's Lymphoma

United States
Institut Bergonié
National Cancer Institute, France

Completed

Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial (FRAIL-06)

Lymphoma

France
University of Florida

Completed

Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy

Hodgkin's Lymphoma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (AVOID)

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

Germany, Italy, Spain
Narendranath Epperla

Withdrawn

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Nodal Marginal Zone Lymphoma | Recurrent Nodal Marginal Zone Lymphoma | Recurrent Splenic Marginal Zone Lymphoma | Refractory Splenic Marginal Zone Lymphoma and other conditions
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
University of Padova

Withdrawn

Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery

Breast Cancer | Anesthesia, Local

Italy
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); The Cleveland Clinic; University of Rochester

Completed

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Lymphoma | Leukemia | Small Intestine Cancer

United States
Shanghai Henlius Biotech

Completed

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

B-cell Non Hodgkin's Lymphoma
Shanghai Henlius Biotech

Completed

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

B-cell Non Hodgkin's Lymphoma

China
Incyte Corporation

Terminated

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Hematologic Malignancies

United States, Spain, France, Italy
Jennifer Woyach
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Sanofi

Completed

Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia (RAISE)

Lymphoma

China
University of Washington
Bayer

Terminated

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Lymphoid Leukemia

United States
Eli Lilly and Company

Completed

A Study of LY3023414 in Participants With Advanced Cancer

Non-Hodgkin's Lymphoma | Metastatic Cancer | Malignant Mesothelioma | Metastatic Breast Cancer | Non-small Cell Lung Cancer | Advanced Cancer

United States, Puerto Rico, Italy
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Central Nervous System Lymphoma | Gastric Mantle Cell Lymphoma | Splenic Mantle Cell Lymphoma

United States

Search clinical trials for: Hodgkin's Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations